Olema Pharmaceuticals Inc (NASDAQ: OLMA) stock jumped 0.25% on Monday to $15.95 against a previous-day closing price of $15.91. With 0.89 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $16.37 whereas the lowest price it dropped to was $15.51. The 52-week range on OLMA shows that it touched its highest point at $17.79 and its lowest point at $2.19 during that stretch. It currently has a 1-year price target of $25.29. Beta for the stock currently stands at 2.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of OLMA was up-trending over the past week, with a rise of 8.14%, but this was up by 50.61% over a month. Three-month performance surged to 67.72% while six-month performance rose 155.61%. The stock gained 490.74% in the past year, while it has gained 551.02% so far this year. A look at the trailing 12-month EPS for OLMA yields -2.32 with Next year EPS estimates of -2.15. For the next quarter, that number is -0.48. This implies an EPS growth rate of 19.23% for this year and -1.53% for next year.
Float and Shares Shorts:
At present, 54.77 million OLMA shares are outstanding with a float of 45.96 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.76 million, which was 5.05% higher than short shares on Sep 28, 2023. In addition to Dr. Sean P. Bohen M.D., Ph.D. as the firm’s President, CEO & Director, Mr. Shane William Charles Kovacs M.B.A. serves as its Chief Operating & Financial Officer.
Through their ownership of 82.83% of OLMA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 85.60% of OLMA, in contrast to 28.44% held by mutual funds. Shares owned by individuals account for 19.93%. As the largest shareholder in OLMA with 22.09% of the stake, BVF Partners LP holds 9,135,893 shares worth 9,135,893. A second-largest stockholder of OLMA, Paradigm BioCapital Advisors LP, holds 7,803,600 shares, controlling over 18.87% of the firm’s shares. Cormorant Asset Management LP is the third largest shareholder in OLMA, holding 4,504,764 shares or 10.89% stake. With a 2.47% stake in OLMA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,022,226 shares are owned by the mutual fund manager. The Polar Capital Funds Plc – Biotech, which owns about 1.81% of OLMA stock, is the second-largest Mutual Fund holder. It holds 750,000 shares valued at 9.97 million. iShares Russell 2000 ETF holds 1.51% of the stake in OLMA, owning 625,854 shares worth 8.32 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for OLMA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With OLMA analysts setting a high price target of $29.00 and a low target of $21.00, the average target price over the next 12 months is $25.29. Based on these targets, OLMA could surge 81.82% to reach the target high and rise by 31.66% to reach the target low. Reaching the average price target will result in a growth of 58.56% from current levels.
Summary of Insider Activity:
Insiders traded OLMA stock several times over the past three months with 4 Buys and 6 Sells. In these transactions, 1,605,488 shares were bought while 100,000 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has risen to 10 over the past year. The total number of shares bought during that period was 1,615,488 while 135,000 shares were sold.